[ad_1]
The best results were obtained when volunteers were inoculated with a half dose of the vaccine, before using a full dose one month later.
The best results were obtained when volunteers were inoculated with a half dose of the vaccine, before using a full dose one month later.
3 ‘reading
After Pfizer-BioNTech and Moderna in the US, the first European vaccine also sees the target. The British multinational AstraZeneca has announced that its vaccine for the new coronavirus, developed together with the University of Oxford, has shown an average effectiveness of 70% in protecting against the virus in two study segments. The high levels of compliance, he said, come from analyzes in Britain and Brazil, and there were no cases of serious illness or hospitalization in the trial participants who received the vaccine.
Effectiveness up to 90%
More specifically, the results of the Covid-19 vaccine developed by the University of Oxford and AstraZeneca with the Pomezia Irbm, combine data from two different doses: one regimen, administered to some 2,700 people, showed an efficacy of 90%, while Another, given to nearly 9,000 people with two full doses a month apart, showed 62 percent effectiveness. The best results were obtained when volunteers were inoculated with a half dose of the vaccine, before using a full dose one month later. The latter will be the vaccine that will be marketed to the public, highlighting the maximum tolerance for the elderly.
Loading…
The other vaccines
The findings are compared with data from Moderna, which said its vaccine prevented 94.5 percent of study participants from getting sick, according to early data. Pfizer, which is working with German partner BioNTech, said its vaccine prevented 95 percent of symptomatic infections. Astrazeneca stated that there were no serious adverse health events and that the vaccine was well tolerated in both dose groups. There were no severe cases of Covid-19 in the study and no participants were hospitalized.
Cheaper than Pfizer and Moderna vaccines
Despite the lower efficacy, the British vaccine has some advantages in terms of distribution. Astra-Oxford vaccine can be kept at refrigerator temperature for at least 6 months, which would facilitate its transportation and storage around the world, especially in low- and middle-income countries. Pfizer’s vaccine, on the other hand, must be transported and stored at -70 degrees, while Moderna’s can stay at refrigerator temperature for up to 30 days. And it will also cost potentially less, ie € 2.80 per dose compared to $ 19.50 for the Pfizer vaccine and $ 25 for the Moderna vaccine.
200 million doses available by the end of 2020
Approximately 200 million doses of the candidate vaccine developed by the University of Oxford will be available worldwide by the end of 2020, approximately four times that of Pfizer. Production will reach 700 million doses next March and 3 billion before the end of 2021. This was stated in a videoconference by Pam Cheng, vice president of the pharmaceutical giant AstraZeneca, a partner of the British university together with Irbm. di Pomezia, explaining with CEO Pascal Soriot that, through a network of 20 production centers around the world, it will be possible to produce 100 to 200 million doses per month for the international market in 2021. The UK has already reserved 20 million doses of the Oxford prototype by the end of the year and another 70 million for the spring.
